Apo A-1 mimetic peptides as atheroprotective agents in murine models.
The mouse has proven to be an excellent model for testing apolipoprotein mimetic peptides as agents to treat a variety of vascular inflammatory conditions including atherosclerosis, cognitive dysfunction associated with arteriole inflammation, chronic rejection of transplanted hearts, and scleroderma. The mechanism of action appears to relate to the ability of these peptides to preferentially bind pro-inflammatory oxidized lipids and is independent of the chirality of the peptides since peptides synthesized from either D- or L-amino acids appear to be equally effective.
Navab
Mohamad
M
Department of Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, California 90095-1679, USA. mnavab@mednet.ucla.edu
Anantharamaiah
G M
GM
Reddy
Srinivasa T
ST
Van Lenten
Brian J
BJ
Fogelman
Alan M
AM
D000818:Animals; D016632:Apolipoprotein A-I / Q000378:metabolism / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000378:metabolism / Q000517:prevention & control*; D040761:Biomimetic Materials / Q000378:metabolism / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D010455:Peptides / Q000378:metabolism / Q000627:therapeutic use*; D011485:Protein Binding / Q000502:physiology
D016632:Apolipoprotein A-I; D010455:Peptides